Alan Swaisland
- Molecular Biology top 10%
- Cancer Research top 5%
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 10%
- Pharmacology top 1%
- Co-authors
- Peter SimsAlan HewerK. PalP.L. GroverGeorgina SpeakeLaura HargreavesDanny RischinPhilip L. Grover
- Topics
- Lung Cancer Treatments and Mutations (5 papers)Chronic Myeloid Leukemia Treatments (4 papers)Colorectal Cancer Treatments and Studies (3 papers)
- Partner nations
- United KingdomUnited StatesBrazil
In The Last Decade
Alan Swaisland
16 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Molecular Biology 815
- Cancer Research 573
- Oncology 541
- Pulmonary and Respiratory Medicine 327
- Pharmacology 290
Countries citing papers authored by Alan Swaisland
This map shows the geographic impact of Alan Swaisland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Swaisland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Swaisland more than expected).
Fields of papers citing papers by Alan Swaisland
This network shows the impact of papers produced by Alan Swaisland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Swaisland. The network helps show where Alan Swaisland may publish in the future.
Co-authorship network of co-authors of Alan Swaisland
This figure shows the co-authorship network connecting the top 25 collaborators of Alan Swaisland. A scholar is included among the top collaborators of Alan Swaisland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Swaisland. Alan Swaisland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 25 | |
| 2 | 11 | |
| 3 | 95 | |
| 4 | Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects. | 4 |
| 5 | 43 | |
| 6 | 267 | |
| 7 | 89 | |
| 8 | 32 | |
| 9 | 6 | |
| 10 | 31 | |
| 11 | 155 | |
| 12 | 13 | |
| 13 | 65 | |
| 14 | Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxidebreakdown → | 951 |
| 15 | 10 | |
| 16 | 39 |
About Alan Swaisland
Alan Swaisland is a scholar working on Hematology, Genetics and Otorhinolaryngology, having authored 16 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Cancer Research (573 citations), Otorhinolaryngology (165 citations) and Pharmacology (290 citations). Alan Swaisland has collaborated with scholars based in United Kingdom, United States and Brazil. Frequent co-authors include Peter Sims, Alan Hewer, K. Pal, P.L. Grover, Georgina Speake, Laura Hargreaves, Danny Rischin, Philip L. Grover, Avgust M. Garin and Chonlakiet Khorprasert. Their work appears in journals such as Nature, Journal of Clinical Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.